Tag Archives: MAP Pharmaceuticals

Unmet Need in the Migraine Space?

Allergan CEO David Pyott is bullish on Botox’s potential as a salve for chronic migraine. He’s also betting on a next-gen dihydroergotamine (DHE) – Levadex – from MAP Pharmaceuticals.
Posted in FDA, Global, Marketing, Regulatory, Strategy, Technology | Also tagged , , , | 2 Comments
  • Categories

  • Meta